Group 1 - The core viewpoint of the news is the acceleration of the industrialization and commercialization of brain-computer interface (BCI) technology in China, supported by a joint policy from multiple government departments [1][2] - The policy emphasizes upgrading smart terminals and supporting breakthroughs in edge models and application toolchains, focusing on AI-enabled devices such as smartphones, computers, tablets, and smart home products [1] - The global BCI industry is experiencing rapid development, with a competitive landscape where the U.S. leads in invasive technologies while China excels in non-invasive approaches [2] Group 2 - Recent announcements from companies like Neuralink indicate plans for large-scale production of BCI devices by 2026, highlighting advancements in fully automated surgical processes [1] - The BCI industry encompasses a wide range of sectors, including materials, chips, surgery, and medical rehabilitation, with significant policy support and healthcare pricing measures in place to facilitate commercialization in China [1][2] - Key competitive factors in the BCI industry include electrodes, chips, and algorithms, with a focus on non-invasive commercialization in the short term and a shift towards flexible electrodes and high-throughput low-power chips in the long term [2]

Group 1 - The core viewpoint of the article highlights a significant decline in brain-computer interface concept stocks, with notable drops in companies such as Nanjing Panda Electronics, Lens Technology, BrainCo, and Micron Brain Science [1] - Nanjing Panda Electronics reported an 8.29% drop to HKD 5.53, while Lens Technology fell by 5.74% to HKD 28.26, BrainCo decreased by 5.7% to HKD 7.11, and Micron Brain Science dropped by 2.23% to HKD 13.15 [1] - Nanjing Panda has stated that its main business focuses on smart transportation, safe cities, industrial internet, and green service-oriented electronic manufacturing, with no current changes or mature products related to brain-computer interfaces [1] Group 2 - Wanlian Securities indicated that the commercialization of brain-computer interfaces is currently more focused on non-invasive methods, while the long-term core lies in (semi) invasive technologies, including flexible electrodes and high-throughput low-power chips [1] - Future industry development catalysts include policy support, medical insurance payments, breakthroughs in clinical registration nodes, core technology advancements, and domestic replacements [1] - For invasive methods, attention should be on research teams, clinical resources, and financing environments, while non-invasive methods should focus on branding, distribution channels, and cost control [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant stock price increases, driven by strong market interest and recent developments in the industry [1] Group 1: Stock Performance - Micron Brain Science (02172) rose by 8.15%, reaching HKD 13.53 [1] - Nanjing Panda Electronics (00553) increased by 7.38%, trading at HKD 6.26 [1] - Lens Technology (06613) saw a rise of 5.07%, priced at HKD 30.26 [1] Group 2: Market Developments - Strong Brain Technology has confidentially submitted an IPO application in Hong Kong after securing approximately CNY 2 billion in funding, marking the second-largest financing record in the BCI field globally, after Neuralink [1] - Elon Musk announced plans to commence large-scale production of BCI devices in 2026, alongside the development of fully automated surgical solutions, expressing confidence in aiding paralysis patients to regain full functionality [1] Group 3: Market Size and Growth Projections - According to Precedence Research, the global BCI market is projected to reach USD 2.62 billion in 2024, increasing to USD 2.94 billion by 2025, and potentially growing to USD 12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% over the next decade [1] - The Chinese BCI market is expected to reach CNY 3.2 billion in 2024, with projections of CNY 6.14 billion by 2028 [1] - The Central Committee of the Communist Party of China emphasizes the development of future industries, including BCI, as new economic growth points, aiming to create a new high-tech industry in China over the next decade [1]

Group 1 - Brain-computer interface concept stocks saw a majority increase in early trading [1][2] - Brain洞极光-B (06681) rose by 9.57%, reaching HKD 7.90 [1][2] - 微创脑科学 (02172) increased by 6.76%, trading at HKD 13.26 [1][2] - 脑洞科技 (02203) experienced a rise of 9.33%, priced at HKD 0.246 [1][2]

Group 1 - The core viewpoint of the article highlights the upward trend in brain-computer interface (BCI) concept stocks, driven by supportive government policies and technological advancements [1] - As of the report, notable stock performances include Brainhole Aurora-B (06681) up 7.91% to HKD 7.78, Micron Brain Science (02172) up 6.2% to HKD 13.19, and Brainhole Technology (02203) up 3.56% to HKD 0.233 [1] - The Ministry of Industry and Information Technology, along with eight other departments, issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'" on January 7, focusing on accelerating the upgrade of smart terminals and emphasizing the industrialization and commercialization of new terminals like AR/VR devices and BCIs [1] Group 2 - Financial analysts believe that the BCI industry is entering a critical phase of scaling applications, supported by strong policy backing, the implementation of medical insurance payments, and continuous technological breakthroughs [1] - Guosen Securities indicates that the BCI sector is at a pivotal point of transitioning from technological breakthroughs to commercialization, driven by a combination of policies, technology, and application scenarios [1] - The industry is expected to benefit from the "14th Five-Year Plan" focus, medical insurance coding, and the establishment of medical device standards, alongside anticipated mass production of Neuralik and breakthroughs in domestic clinical applications, leading to explosive growth in the global market [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02172 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1 ...

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a decline, with MicroPort NeuroTech (02172.HK) dropping over 7% [1] - Nanjing Panda Electronics Co., Ltd. (00553.HK) and BrainCo Inc. (06681.HK) both fell nearly 6% [1] - Xinwei Medical-B (心玮医疗-B) saw a decline of nearly 3% [1]

Market Overview - The Hong Kong stock market showed a narrow range of fluctuations on January 5, with the Hang Seng Index slightly up by 0.03%, the Hang Seng China Enterprises Index down by 0.22%, and the Hang Seng Tech Index up by 0.09% [1][2]. Sector Performance - Large tech stocks exhibited mixed performance, with Kuaishou surging by over 11%, while other notable stocks like Bilibili and Alibaba also saw gains of over 5% and 2%, respectively. Conversely, stocks like NetEase and Xiaomi fell by over 2% [2][4]. - The biotechnology sector was active, with companies like Rongchang Bio and Kelun-Bothai rising over 7%, and other firms like Fuhong Hanlin and Tigermed increasing by over 6% [7]. - The insurance sector saw strong gains, with China Pacific Insurance up over 6% and New China Life Insurance up over 5%. Analysts highlighted five key trends in the life insurance industry for 2026, including rapid growth in new business and a shift in customer demographics [8]. - The automotive sector faced declines, with Great Wall Motors dropping over 6% and NIO nearly 6%. Despite some brands achieving record sales in 2025, only a few met their annual sales targets [10]. Notable Stock Movements - Kuaishou's stock price reached 73.60 HKD, reflecting an increase of 11.09% with a market cap of 317.91 billion HKD [5]. - Nanjing Panda Electronics surged by nearly 40%, while Micron Brain Science and Brainhole Technology rose by nearly 20% and over 17%, respectively, following news of Neuralink's plans for large-scale production of brain-computer interface devices [6][4]. - The "three oil giants" saw significant declines, with China Petroleum and China National Offshore Oil Corporation both dropping over 3% due to geopolitical tensions and OPEC+ decisions [9]. Capital Flows - Southbound funds recorded a net inflow of 18.723 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing 9.809 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing 8.914 billion HKD [12]. Future Outlook - Goldman Sachs recommends overweighting Chinese stocks, predicting a 15% to 20% annual increase in the Chinese stock market for 2026 and 2027. Guosen Securities also sees potential in the market driven by a weaker US dollar and improved domestic liquidity in the spring of 2026 [15].

Group 1: Neuralink and Brain-Computer Interface Stocks - Neuralink, founded by Elon Musk, plans to start large-scale production of brain-computer interface devices in 2026, leading to a significant surge in related stocks [1] - Nanjing Panda Electronics (00553) saw a rise of over 44%, while other companies like Xinwei Medical-B (06609), Micron Brain Science (02172), and Brainhole Laser-B (06681) increased by 11.90%, 17%, and 19.8% respectively [1] Group 2: Pharmaceutical Sector Performance - The pharmaceutical sector showed strong performance, with China's innovative drug licensing exceeding $100 billion last year [1] - Companies such as Gilead Sciences-B (01672), Cloudtop New Medicine (01952), and Innovent Biologics (01801) experienced stock increases of 8.85%, 5.65%, and 6.28% respectively [1] Group 3: Robotics and Technology Stocks - Woan Robotics (06600) saw its stock rise by over 27%, with a midday increase of 19.57% as it prepares to launch its first humanoid household robot [1] - The company reported a compound annual growth rate of 49% in revenue over the past three years [1] Group 4: Other Notable Stock Movements - Kuaishou-W (01024) increased by over 9%, with foreign investors optimistic about its revenue outlook for next year [1] - Fuhong Hanlin (02696) rose by 7% after three of its innovative cancer drugs received IND acceptance [1] - Kelun-Biotech (06990) gained over 7% following the approval of its clinical trial application for the new drug ITGB6 ADC SKB105 [2] - The Golden Group (03939) increased by 3.94% due to the successful implementation of key projects at the Solomon Gold Mine [3]

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].